RIPA-56
Based on 9 publication(s) in Google Scholar
RIPA-56 is a highly potent, selective, and metabolically stable inhibitor of receptor-interacting protein 1 (RIP1) with an IC50 of 13 nM. RIPA-56 can be used for the treatment of systemic inflammatory response syndrome.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté: 99.94%
- CAS No.: 1956370-21-0
- Formule: C13H19NO2
- Masse moléculaire:221.30
-
Stockage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
-
Solvant et solubilité
- Protocole
- Pureté et documentation
- Références
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) RIPA-56
More- EBioMedicine. 2024 Jan:99:104920. [Abstract]
- NPJ Precis Oncol. 2025 Apr 16;9(1):112. [Abstract]
- J Med Chem. 2026 May 28;69(10):12069-12098. [Abstract]
- Thromb Haemost. 2024 Jun;124(6):568-580. [Abstract]
- J Neurochem. 2025 Oct;169(10):e70246. [Abstract]
- Exp Cell Res. 2024 Mar 15;436(2):113980. [Abstract]
- Stem Cells Dev. 2020 Apr 15;29(8):475-487. [Abstract]
- Pediatr Discov. 2024 Jul 9;2(4):e94. [Abstract]
- Patent. US20220362179A1.
Activité biologique
IC50: 13 nM (RIP1)[1]
RIPA-56 shows efficient inhibition of RIP1 kinase activity, with an IC50 of 13 nM and no inhibition of RIP3 kinase activity at a 10 μM concentration. RIPA-56 also demonstrates potency in protection of murine L929 cells from TNFα/z-VAD-FMK (TZ)-induced necrosis (EC50=27 nM)[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
CAS No. 1956370-21-0
-
Appearance Solid
-
Masse moléculaire 221.30
-
Formule C13H19NO2
-
Color White to off-white
-
SMILES
CCC(C)(C)C(N(CC1=CC=CC=C1)O)=O
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 2 years -20°C 1 year
Publications (9)
-
Journal Impact Factor
-
Most Recent
-
EBioMedicine
Analysis of multiple programmed cell death-related prognostic genes and functional validations of necroptosis-associated genes in oesophageal squamous cell carcinoma. [Abstract]2024 Jan:99:104920. PMID: 38101299 -
NPJ Precis Oncol
Integrating bulk, single-cell, and spatial transcriptomics to identify and functionally validate novel targets to enhance immunotherapy in NSCLC. [Abstract]2025 Apr 16;9(1):112. PMID: 40240582 -
J Med Chem
Discovery of LT-1339-553 as a Potent RIPK1 Inhibitor for Schistosomiasis-Induced Hepatic Fibrosis. [Abstract]2026 May 28;69(10):12069-12098. PMID: 42142075 -
Thromb Haemost
Macrophage ferroptosis promotes MMP2/9 overexpression induced by hemin in hemorrhagic plaque. [Abstract]2024 Jun;124(6):568-580. PMID: 37696298 -
J Neurochem
Neuronal Damage Induced by Gradual Oxidative Stress in iPSC-Derived Neurons: Implications for Ferroptosis Involvement and ALS Drug Evaluation. [Abstract]2025 Oct;169(10):e70246. PMID: 41017138 -
Exp Cell Res
2024 Mar 15;436(2):113980. PMID: 38401686 -
Stem Cells Dev
Inhibiting Necroptosis of Spermatogonial Stem Cell as a Novel Strategy for Male Fertility Preservation. [Abstract]2020 Apr 15;29(8):475-487. PMID: 32024413 -
Pediatr Discov
SOX9 regulates epithelial-mesenchymal transformation by mediating the Wnt/ β-catenin signaling pathway in hypospadias. [Abstract]2024 Jul 9;2(4):e94. PMID: 40626133 -
Solvant et solubilité
DMSO : ≥ 100 mg/mL (451.88 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
* "≥" means soluble, but saturation unknown.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (11.30 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (11.30 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Protocole
Cell necrosis assay is performed in 96-well cell culture plate. 3,000 cells are plated in each well and cultured at 37°C overnight. HT-29 cells are treated with 20 ng/mL TNFα/100 nM Smac Mimetics/20 μM z-VAD-FMK and RIPA-56 for 24 h. L929 cells are treated with 20 ng/mL TNFα/20 μM z-VAD-FMK and RIPA-56 for 6 h. The cell survival ratio is determined using the Cell Titer-Glo Luminescent Cell Viability Assay kit[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Mice: Following intraveneous (IV), intraperitoneal (IP), or oral administration (PO) of RIPA-56 to C57BL/6 mice (n=3), blood is sampled through eye puncture at various time points. Compound concentrations in the plasma samples are analyzed by LCMS/MS. Pharmacokinetic parameters are determined from individual animal data using noncompartmental analysis in phoenix 64[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Pureté et documentation
-
Fiche technique (275 KB)
-
SDS (254 KB)
- English - EN (254 KB)
- Français - FR (254 KB)
- Deutsch - DE (254 KB)
- Norwegian - NO (254 KB)
- Español - ES (254 KB)
- Swedish - SV (254 KB)
- Italian - IT (254 KB)
- Korean - KR (254 KB)
- Portuguese - PT (254 KB)
-
Instruction de manipulation (2659 KB)
Références
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 4.5188 mL | 22.5938 mL | 45.1875 mL | 112.9688 mL |
| 5 mM | 0.9038 mL | 4.5188 mL | 9.0375 mL | 22.5938 mL | |
| 10 mM | 0.4519 mL | 2.2594 mL | 4.5188 mL | 11.2969 mL | |
| 15 mM | 0.3013 mL | 1.5063 mL | 3.0125 mL | 7.5313 mL | |
| 20 mM | 0.2259 mL | 1.1297 mL | 2.2594 mL | 5.6484 mL | |
| 25 mM | 0.1808 mL | 0.9038 mL | 1.8075 mL | 4.5188 mL | |
| 30 mM | 0.1506 mL | 0.7531 mL | 1.5063 mL | 3.7656 mL | |
| 40 mM | 0.1130 mL | 0.5648 mL | 1.1297 mL | 2.8242 mL | |
| 50 mM | 0.0904 mL | 0.4519 mL | 0.9038 mL | 2.2594 mL | |
| 60 mM | 0.0753 mL | 0.3766 mL | 0.7531 mL | 1.8828 mL | |
| 80 mM | 0.0565 mL | 0.2824 mL | 0.5648 mL | 1.4121 mL | |
| 100 mM | 0.0452 mL | 0.2259 mL | 0.4519 mL | 1.1297 mL |
RIPA-56 Related Classifications
HY-101032 Related Classifications
Powered by Bioz